- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02207010
A Phase 0 Study of AZD1775 in Recurrent GBM Patients
A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration
This study would test how much of the new drug, AZD1775, is present in tumor, blood, and skin after one dose of the drug.
The purpose of the study is not to treat the tumor, but to see if the drug actually gets into the tumor cells. This study does not replace routine cancer treatment.
Study Overview
Detailed Description
Patients will be administered one dose of AZD1775 prior to surgical resection of their tumor. There will be 2 portions of this trial, referred to as Part 1 and Part 2. Part 1 will involve a dose escalation strategy where 3 separate doses (100, 200, and 400mg) will be evaluated. Each dose cohort will involve 4 patients. Surgery, with tissue harvest for determination of both tissue drug level and biomarker evaluation, will occur at 8 hrs post drug administration.
Part 2 will determine the potential tumor drug level and PD effects at various time intervals after drug administration of a single select drug dose. Currently, we are planning to use a dose (200 mg) that has been deemed safe when used in combination with cytotoxic therapy. However, if results from Part 1 suggest an alternate dose may be preferable, we will consider using that alternate dose in Part 2. Dosing will be followed by surgical resection at 2-4 hrs and at 22-26 hrs post dose.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Barrow Neurological Institute at St. Joseph's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with 1 prior resection of histologically-diagnosed de novo GBM
- Patient must have MRI evidence of disease recurrence
- Patients must have Eastern Cooperative Oncology Group (ECOG) performance status ≤2
- Patients ≥ 18 years of age
- Adequate hematologic, renal, and hepatic function
- Patients must not have co-morbid condition(s) that, at the opinion of the investigator, prevent safe surgical treatment
- Patients must not have active infection or fever > 38.5°C
- Patients must not be pregnant or nursing
- Patients must have archival tumor tissue block available for research use
- Ability to understand and the willingness to sign a written informed consent document.
- Patient has voluntarily agreed to participate by giving written informed consent.
Exclusion Criteria:
- Less than 18 years of age
- Diagnosis of anything other than first-recurrence GBM
- GBM tissue from first-resection not available
- Previous treatment with AZD1775
- Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Patient has known hypersensitivity to the components of potential study therapy or its analogs.
- Patient has had prescription or non-prescription drugs or other products known to be metabolized by cytochrome P450 3A4 (CYP3A4), or to inhibit or induce CYP3A4, which cannot be discontinued prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of study medication (inhibitors generally for 5 half-lives). Medications of particular concern are the following inhibitors of CYP3A4: azole antifungals (ketoconazole itraconazole, fluconazole and voriconazole), macrolide antibiotics (erythromycin, clarithromycin), cimetidine, HIV protease inhibitors, nefazodone and the following inducers of CYP3A4: phenytoin, barbiturates and rifampicin. Substrates of CYP3A4 include statins (lovastatin, simvastatin), midazolam, terfenadine, astemizole, and cisapride. CYP3A4.
- Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
- Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
- Patients expecting to reproduce within the projected duration of the study (estimated to be 1 year), and women who are pregnant or breastfeeding.
- Patient is known to be suffering from Acquired Immune Deficiency Syndrome (AIDS).
- Patient has known history of Hepatitis B or C.
- Patient has symptomatic ascites or pleural effusion. A patient who is clinically stable following treatment for these conditions is eligible.
- Patient has a clinical history suggestive of Li-Fraumeni Syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AZD1775
Patients will receive a single dose (either 100 mg, 200 mg or 400 mg) of AZD1775, an oral agent, prior to surgery for resection of GBM
|
All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Plasma concentration of AZD1775 following single dose of AZD1775
Time Frame: at baseline, 2-4, 8-12, and 22-26 hours following single dose of AZD1775
|
Will be summarized using descriptive statistics
|
at baseline, 2-4, 8-12, and 22-26 hours following single dose of AZD1775
|
Intratumoral concentration of AZD1775
Time Frame: up to day of surgery
|
Will be summarized using descriptive statistics
|
up to day of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Degree of CDC2 (Tyr15) phosphorylation in tissue
Time Frame: at baseline and up to 26 hours post dosing
|
Will be summarized using descriptive statistics
|
at baseline and up to 26 hours post dosing
|
Number of GBM cells in M-phase of cell cycle (PH3)
Time Frame: at baseline and up to 26 hours post dose AZD1775
|
Will be summarized using descriptive statistics
|
at baseline and up to 26 hours post dose AZD1775
|
Presence of double-strand DNA damage (γH2AX).
Time Frame: at baseline and up to 26 hours post dose AZD1775
|
Will be summarized using descriptive statistics
|
at baseline and up to 26 hours post dose AZD1775
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
P53 mutation status
Time Frame: up to time of surgery
|
Will be summarized using descriptive statistics
|
up to time of surgery
|
Presence of checkpoint regulator genes in GBM specimens
Time Frame: up to time of surgery
|
checkpoint regulator genes in GBM specimens
|
up to time of surgery
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Nader Sanai, MD, Barrow Neurological Institute at St.Joseph's Hospital Medical Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BBTRC 001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma
-
Celldex TherapeuticsCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component | Relapsed GlioblastomaUnited States
-
Juan M Garcia-GomezHospital Universitario 12 de Octubre; Hospital Clínico Universitario de ValenciaRecruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Astrocytoma, Grade IV | Glioblastoma, IDH-mutant | Glioblastoma, IDH-wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype | Glioblastoma IDH (Isocitrate Dehydrogenase) MutantSpain
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States, Belgium, Switzerland, Germany, Netherlands
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... and other collaboratorsRecruitingGlioblastoma | Glioblastoma Multiforme | Recurrent Glioblastoma | Glioblastoma, IDH-wildtype | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of Brain | Astrocytoma of Brain | Astrocytoma, MalignantUnited States, Germany, Netherlands, Switzerland, Belgium
-
Leland MethenyNational Cancer Institute (NCI)RecruitingGlioblastoma Multiforme | Supratentorial Gliosarcoma | Glioblastoma Multiforme, Adult | Supratentorial GlioblastomaUnited States
-
Northwestern UniversityAgenus Inc.; CarTheraRecruitingGlioblastoma Multiforme | Gliosarcoma | Newly Diagnosed Glioblastoma | Glioblastoma, Isocitric Dehydrogenase (IDH)-WildtypeUnited States
-
University Hospital, GenevaActive, not recruitingGlioblastoma Multiforme | Glioblastoma Multiforme of Brain | Glioma of Brain | Glioblastoma, AdultSwitzerland
-
Milton S. Hershey Medical CenterRecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingGlioblastoma | Astrocytoma | Recurrent Glioblastoma | MGMT-Unmethylated Glioblastoma | Glioblastoma, IDH-WildtypeUnited States
-
Milton S. Hershey Medical CenterNational Cancer Institute (NCI)RecruitingGlioblastoma | Glioblastoma Multiforme | Glioblastoma Multiforme, Adult | Glioblastoma Multiforme of BrainUnited States
Clinical Trials on AZD1775
-
NYU Langone HealthTerminatedAcute Myeloid Leukemia | Myelodysplastic Syndromes | MyelofibrosesUnited States
-
AstraZenecaTerminatedPreviously Treated Non Small Cell Lung CancerUnited States
-
AstraZenecaCompletedOvarian Cancer | Locally Advanced Solid Tumours | Metastatic Solid TumoursUnited States
-
AstraZenecaParexelTerminatedAdvanced Solid TumoursUnited Kingdom, United States
-
Samsung Medical CenterCompletedSmall Cell Lung CancerKorea, Republic of
-
AstraZenecaParexelCompletedUterine Serous CarcinomaUnited States, Italy, Spain, France, Canada
-
Samsung Medical CenterTerminated
-
Dana-Farber Cancer InstituteAstraZenecaActive, not recruitingUterine CancerUnited States
-
AstraZenecaQuintiles, Inc.CompletedSolid TumoursFrance, United Kingdom, Netherlands
-
AstraZenecaTerminatedPreviously Untreated Stage IV Non-Squamous Non Small Cell Lung CancerUnited States